Skip to main content

Table 1 Baseline patient characteristics (n = 31)

From: A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer

Characteristics

N (%)

Age (years)

 Median

69

 Range, interquartile range

(37–86, 61–73)

Gender

 Male

21 (68)

 Female

10 (32)

ECOG performance status

 0

13 (42)

 1

16 (52)

 2

2 (6)

Primary tumor location

 Colon

25 (81)

 Rectum

6 (19)

Primary resected

 Yes

26 (84)

 No

5 (16)

No of metastatic site,

 1

10 (32)

 2

9 (29)

  ≥ 3

12 (39)

Metastatic sites

 Liver

22 (71)

 Lung

17 (55)

 Lymph nodes

13 (42)

 Peritoneum

9 (29)

 Other

4 (13)

KRAS mutation

 Yes

13 (37)

 No

18 (63)

BRAF mutation

 Yes

2 (6)

 No

26 (84)

 Unknown

3 (10)

Number of lines prior therapy

 2

8 (19)

 3

16 (59)

  ≥ 4

7 (22)

Median CEA level ng/ml (range, interquartile range)

116 (0–42,230, 31–350)

Median CA19-9 level ng/ml (range, interquartile range)

222 (5–9820, 38–965)

  1. ECOG Eastern Cooperative Oncology Group, CEA serum carcinoembryonic antigen, CA19-9 carbohydrate antigen 19–9